Yes, the word out there is that these two deals are expected to finish the IPO year with a bang: Bellicum Pharmaceuticals (BLCM - proposed) and Juno Therapeutics (JUNO – proposed). Let’s take a closer look at the pending dynamic duo.
Bellicum Pharmaceuticals, based in Houston, is a clinical-stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders.
One of Bellicum’s leading product candidates, BPX-501, is designed to eliminate the risk of Graft versus Host Disease in patients who have undergone stem cell transplants for leukemia and other types of cancer. Bellicum is also developing a vaccine for ...